chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Migratory pain in all joints and muscles for approx 8 hrs followed by exhaustion and muscle pain for 24 hrs. Pain on day 2 , 3/16 was greater in lower back and hips.  Residual muscle soreness and weakness on 3/17. Initial pain jumped from joint to joint .  Intense enough to prevent any sleep.  Out of commission for 36 hrs.
All the patients who received a vaccine which was more than 30 days in the refrigerator; All the patients who received a vaccine which was more than 30 days in the refrigerator; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (All the patients who received a vaccine which was more than 30 days in the refrigerator) and PRODUCT STORAGE ERROR (All the patients who received a vaccine which was more than 30 days in the refrigerator) in a 50-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 28-Jul-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (All the patients who received a vaccine which was more than 30 days in the refrigerator) and PRODUCT STORAGE ERROR (All the patients who received a vaccine which was more than 30 days in the refrigerator). At the time of the report, EXPIRED PRODUCT ADMINISTERED (All the patients who received a vaccine which was more than 30 days in the refrigerator) and PRODUCT STORAGE ERROR (All the patients who received a vaccine which was more than 30 days in the refrigerator) outcome was unknown.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitants were provided. No treatment was provided.
heart palpitations, tired, chest pain, anger outbursts, diarrhea , head ache.
Injection site- redness, pain, heat, slight swelling and shivering several hours after dose . as of 7/25/2023 redness, pain, heat, slight swelling persist , feeling cold has passed, injection site now itches
c/o neck pain started @ night on the day of the vax; felt quite warm, chills, & c/o nausea; 2nd day p/immun felt more fever-still nauseated; 30JAN92 TC to pt no fever, chills or nausea;
pt recv vax w/2 doses of vax in 1997 & pt exp serology negative;
This spontaneous report was received from a physician via field representative refers to a 27 year old female patient. Information regarding patient's medical history, concurrent condition, drug reactions/allergies and concomitant medication were not provided. On 22-JAN-2016, the patient was vaccinated with a dose of PNEUMOVAX 23 (lot # L038669, expiry date: not provided). The patient experienced pain and lumpiness near the injection site, on the same day after receiving the vaccine. She went back to the physician's office on 25-JAN-2016 to seek treatment for site pain. She was provided with an unspecified treatment for the pain and was fine now. Outcome of injection site pain was reported as recovered while injection site lump was unknown. Reporting physician did not assessed the causality of the events with respect to vaccination with PNEUMOVAX 23. Additional information has been requested.
24 hours after vaccination, I had a chill (not a shaking chill) and felt some aches -- just not normal 30 hours after vaccination I had a temp of 99.2.  42 hours after vaccination I felt fine
Around 11:30 a.m ACTHIB (Sanofi) was given to left thigh, uneventfully. Around 3:15 p.m mother called that baby is crying and shaking. Was advised to come to the office (lives close by the office and mother was very scared). Baby was crying a lot, and shaking. The left thigh where the vaccine was given was red and very painful. Then the baby turn pale, with sweating. Mother wanted to give her breast, but baby did not open the mouth. His heart rate was 200/min. Cold compress to left thigh and TYLENOL supp. was given. After a few minutes, the entire face turn red and passed loose watery stool. Then slowly come back to normal. His color and the heart rate went down to 160, then 140. Rectal temp. was 99.2. Kept under observation until 4pm, then went home. Follow-up call was reassuring. Baby was fine.
swelling @ inj site (6cm x 6cm) still persists 7 days post inj; fever 101.8 persistant since 7OCT-12OCT
Fifteen minutes after getting vaccine passed out and went unconscious. Heart rate 148 and 02 at 85. Placed on 2l02 and brought to hospital to where I was dischsrhed.
Information has been received on 08-OCT-2018 regarding a case in litigation from a lawyer and a female consumer of unknown age. The patient's concurrent conditions, medical history and concomitant medications are unknown. On or about 27-SEP-2012, the patient was inoculated with ZOSTAVAX (lot number and expiration unknown) unknown route by a physician at a physician's office as recommended for routine adult health maintenance and for the long-term prevention of shingles. The vaccine did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster or shingles. On or about 31-JAN-2014, the patient was treated by a physician at a physician's office for the onset of a severe vesicular rash, which was diagnosed as herpes zoster or shingles. The patient was prescribed prednisone and VALTREX for management of her painful symptoms and chronic pain. As a direct and proximate result of the ZOSTAVAX and/or despite receiving the ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses and pain and suffering and other damages. Additional information has been requested.
febrile/fever; chills; muscle-ache; Drug dose administration interval too long; sever fatigue; pain / in the eyes and between eyes; redness in the eyes and between eyes; This case was reported by a pharmacist via call center representative and described the occurrence of fever in a 70-year-old male patient who received Herpes zoster (Shingrix) (batch number AP545, expiry date 25th January 2023) for prophylaxis.   Previously administered products included Shingrix (received 1st dose of Shingrix on 6th November 2020).   On 14th May 2021, the patient received the 2nd dose of Shingrix. On 14th May 2021, unknown after receiving Shingrix, the patient experienced drug dose administration interval too long. In May 2021, the patient experienced fever, chills, muscle pain, fatigue, facial pain and eye red. In May 2021, the outcome of the fever, chills and muscle pain were recovered/resolved. On an unknown date, the outcome of the fatigue, facial pain and eye red were not recovered/not resolved and the outcome of the drug dose administration interval too long was unknown.   It was unknown if the reporter considered the fever, chills, muscle pain, fatigue, facial pain and eye red to be related to Shingrix.  Additional details were provided as follow: The patient received 2nd dose of Shingrix and experienced fever, chills, muscle pain, fatigue, pain in and between eye and redness in and between eye. The patient received 2nd dose of Shingrix, more than the recommended interval, which led to lengthening of vaccination schedule. The patient was currently experiencing sever fatigue, pain and redness in the eyes and between eyes.  The reporter consented to follow up
Information has been received from a registered nurse concerning an 80 year old female who on 03-NOV-2006 was vaccinated with a dose of Varivax instead of varicella-zoster virus vaccine. It was reported that this was not a product confusion issue, but new staff employee error. Unspecified medical attention was sought. The patient has not experienced any adverse reaction. No further information was provided. There was no product quality complaint involved. Additional information has been requested.
Wants to sleep all day; very weak; chills, shivering; This spontaneous case was reported by a consumer and describes the occurrence of SOMNOLENCE (Wants to sleep all day), ASTHENIA (very weak) and CHILLS (chills, shivering) in a 71-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 24-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Oct-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 26-Oct-2021, the patient experienced SOMNOLENCE (Wants to sleep all day), ASTHENIA (very weak) and CHILLS (chills, shivering). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at an unspecified dose and frequency. At the time of the report, SOMNOLENCE (Wants to sleep all day), ASTHENIA (very weak) and CHILLS (chills, shivering) had not resolved.            Concomitant medication was not reported.     This case was linked to MOD-2021-364713 (Patient Link).
Administration of only the diluent portion; Administration of only the diluent portion; This case was reported by a pharmacist via call center representative and described the occurrence of inappropriate preparation of medication in a patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown.  Additional details were provided as follows: The age at vaccination was not reported. The reported stated that there was administration of only the diluent portion of the vaccine to the  patient. The reporter did not have information regarding the date of the administration nor gender or age of the patients.  The reporter agreed to be contacted for follow-up and claimed the would try to find more details about the event. No further events were reported.  The reporter consented to follow up. The case was linked with the case US2021AMR222484 reported by same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR222484:Same reporter. Patient 2.
didn't feel well; This case was reported by a consumer via call center representative and described the occurrence of feeling unwell in a adult female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced feeling unwell. On an unknown date, the outcome of the feeling unwell was recovered/resolved.   It was unknown if the reporter considered the feeling unwell to be related to Shingrix.  Additional details were provided as follows: This case was reported by the patient's sister in law. The age at vaccination was not reported. The patient received Shingrix and she did not feel well for a day after the shot.  No additional details were available. The reporter consented to follow up. This case has been linked to US2020053228 and US2020053230, reported by the same reporter.
I was diagnosed with ovarian cancer, a juvenile granulosa cell tumor to be exact. It had been growing for approximately 10 months, which is very near the date when I received the final vaccine and my periods stopped coming. By the time the tumor was caught, it had burst and I was bleeding to death. I had a major surgery. I'm still in remission.
I started to feel right leg pain in morning on 12/19/2021. Especially when I sit down, severe pain when I drive car.
Patient is an 82yo man with PMH significant for remote h/o prostate cancer treatment with IMRT (no hormone tx) 12 years ago and HTN, who presented to the ED with diffuse petecchiae and was found to have a PLT count of 0. Patient reports being in his usual state of excellent health until 2 days ago, when he had a routine PCP visit during which he received the Shingrix vaccine. The following day, he developed diffuse body aches and malaise, and started noticing petecchiae on his LEs and face. No other bleeding including no gum bleeding, hemoptysis, hematuria, or blood in his stool or dark stools. Of note, he was prescribed Ibuprofen by his PCP for a painful toe about a week ago, which had had been taking for 3-4 days prior to admission and takes a baby aspirin nightly. Did not had fevers at home, no periods of confusion or altered MS, no recent unintentional weight loss, fever/chills or drenching sweats.   Patient was seen by Hem/Onc. The differential for thrombocytopenia was wide. TTP was thought to be unlikely as there was no increase in schistocytes on smear, Hgb was normal (12g/L), and pt didn't have any renal dysfunction. In terms of HIT, he did not have recent exposure to heparin, has not been hospitalized recently. Other considerations included thrombocytopenia due to new medications (recently started Ibuprofen, which could be a possible culprit), sequestration (no e/o splenomegaly on exam, and one would not expect such a dramatic drop in PLT counts), no h/o excessive alcohol use. DIC in the setting of an acute infection or malignancy was also thought to be possible, but patient's coags were normal, and fibrinogen is elevated, essentially ruling out DIC. Severe nutritional deficiencies can also cause thrombocytopenia but again, Heme/Onc reports would not expect such a severe degree of thrombocytopenia so acutely and would also expect some degree of anemia.   Most likely on the Heme/Onc differential is immune thrombocytopenia most likely caused by Shingrix vaccine he received on 6/12/19, 1 day prior to onset of symptoms, based on the close temporal relationship. Heme/Onc providers found no published case reports of this, however, in the FDA approval document for Shingrix, there is mention of 5 cases of thrombocytopenia observed during the study period (4 in the Shingrix group and 1 in the placebo group), however, all of these were observed after 100 days post-vaccination and after the second dose of the vaccine. Degree of thrombocytopenia is not reported in the document. Such severe and acute onset of thrombocytopenia has not been reported to our knowledge.  Patient was started on dexamethasone 40mg PO QAM for 4 days total, received 1 g/kg/day x2 days, and received 2 units of pooled platelets. His platelet count recovered from 0--> 7 --> 14 --> 16 --> 24 --> 34 over the course of his hospitalization (6/14-6/16). Patient was discharged with plan to complete dexamethasone course and to recheck platelet count in 5 days. Symptoms: Rash, Purpura & THROMBOCYTOPENIA (platelets 0) Treatment: DEXAMETHASONE 40 MG EVERY DAY, GLOBULIN IMMUNE 67 GM ONCE, GLOBULINIMMUNE 67 GM ONCE
PATIENT RECEIVED 2ND BOOSTER AT THE AGE OF 46 WITHOUT MEETING CURRENT REQUIREMENTS FOR 2ND BOOSTER.
Awoke 2 AM 8/23/08 with severe headache, nausea, nasal congestion. Seen in office 8/23 AM - exam unremarkable, treated with Tylenol 1000 mg reassurance.
Severe lower back ache that began the day after the injection. My backache lasted 5 days.
Pt received PNEUMOVAX injection on 3/15/10. Pt. stated he had approx 8-10 days of (L) u arm edema (from anticub to shoulder), erythema and pain. Pt. had limited ROM and pain during this time.
patient tested positive today 3/22. received 2 doses of vaccine first on 12/30/20 and second 1/20/21
Vaccine was given on 1-10-14, on 1-12-14 patient states arm was very sore. Had a low grade fever and a rash on arms an trunk. States lasted till 1-14-14 and rash and fever subsided. Presented requesting note stating she could return to work. I spoke with Dr and inst to write patient a note to return to work.
Symptoms: Chills, fever, skin sensitivity, body aches, headache.   Treatment: plenty of fluids, rest, Tylenol, cold rag on head. Outcome: still struggling through symptoms as of 12:30 pm the next day.
This spontaneous report as received from a physician via a company representative refers to a patient of unknown age and gender. The patient was vaccinated with the first and the second dose of GARDASIL (lot# unspecified) (dose, route and location unspecified) respectively on unknown date. On an unspecified date after vaccinations, the patient had lymph node swelling and began to cough up blood. At the time of report, the patient had not recovered from the events. The patient had sought medical attention via went to see the physician. Additional information has been requested.
Covid19 vaccine given after being stored at room temperature for 25 hours. Contacted manufacturer and maximum storage at room temperature should be 12 hours due to sterility concerns. No adverse event of infection or injection site reaction recorded. waiting for manufacturer response whether to redose patient.
Case number PHEH2013US0211241 is an initial spontaneous report received from a health care professional on 09 OCT 2013 and a follow up information received on 18 NOV 2013. This refers to a 39-year-old female patient. Her medical history and concomitant medications were unknown. She was vaccinated with FLUVIRIN 2013/2014 (batch number: 1308901, expiry date: Apr 2014) intramuscularly in the left deltoid at 0.5 ml on 07 OCT 2013. Immediately after vaccination on the same date, she complained of 4 to 5 inches itching, redness, soreness, swelling and induration at the injection site. The outcome was reported as complete recovery on 09 OCT 2013. No seriousness and causality were reported.   Follow up information received on 18 NOV 2013. Patient demographics (date of birth, height and weight), site of vaccination , vaccination date, onset date, stop date and outcome of the event updated.
Pt described later after she got home a "warm sensation in her chest and felt like she swallowed a golf ball". Felt similar to GERD she had in the past but she has not had anything other than the shot to trigger this reaction
Patient inadvertently received a 5th shot of the Moderna Covid vaccine; This spontaneous case was reported by a nurse and describes the occurrence of EXTRA DOSE ADMINISTERED (Patient inadvertently received a 5th shot of the Moderna Covid vaccine) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received fifth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXTRA DOSE ADMINISTERED (Patient inadvertently received a 5th shot of the Moderna Covid vaccine). At the time of the report, EXTRA DOSE ADMINISTERED (Patient inadvertently received a 5th shot of the Moderna Covid vaccine) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant medications were reported.  The Nurse stated that One of their patient inadvertently received a 5th shot of the Moderna Covid vaccine.The patient had forgotten she had received 4 injections and the last one did not come across from state database into their system. So they only had 3 documented shots.Her Provider has been notified.  No Treatment information was provided.
Itchy light red rash approximately 3 to 4 inches on the right arm in the vicinity of the injection site.  This appeared 15 days *after* the vaccine was given.  The rash is slightly warm to the touch in comparison aside of the rash area of the arm.
one day after 1st vaccine everything I ate tasted like salt.  My mouth tasty salty 24/7. Symptom lasted 1.5 weeks.  Did not have same reaction with the second vaccine
3:30 pm, c/o not feeling well, tired, feverish 102 at 3:30 pm and this am. Dizzy and pale, c/o pain in left shoulder on movement.
pt recv vax 4APR96 & 20APR96 pt devel a maculopapular rash on the hands * feet;pt recovered by 30APR96;
A patient is 15 and was given the first dose of the Moderna Covid19 Vaccine.; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (A patient is 15 and was given the first dose of the Moderna Covid19 Vaccine.) in a 15-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012F21A) for COVID-19 vaccination.     No Medical History information was reported.    On 21-Oct-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 21-Oct-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (A patient is 15 and was given the first dose of the Moderna Covid19 Vaccine.). On 21-Oct-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (A patient is 15 and was given the first dose of the Moderna Covid19 Vaccine.) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications were not reported. Treatment medications were not reported.
Pulmonary embolism treated with blood thinner.  NO prior history of clotting.
This spontaneous report as received from a health professional refers to an unspecified number of patients. On unknown dates the patients were vaccinated with doses of improperly stored of RECOMBIVAX HB (lot #, expiration date, dose and route unspecified). No adverse events were reported. No additional information was available at that time. This is one of several reports received from same source. Additional information has been requested.
Received vaccine 2-15-2021 about 7:00 pm.  Early  AM on  2-18-21, I awakened to find that I had muscle weakness and impairment on my left side from shoulder down through my foot. I lost dexterity on all left side- mainly fingers of left hand and food (including foot drop and impaired gait) My balance was also affected. I've regained most use
This spontaneous report was received from a registered nurse, and refers to a patient of unknown age and gender. No information was provided regarding the patient's medical history, previous drug reactions, allergies, concurrent conditions or concomitant medications. It was reported that on 29-JAN-2018, the patient received improperly stored dose of VARIVAX (lot # N017394, expiration date 07-JUN-2019) subcutaneously (dose and anatomical location were not reported) for prophylaxis. The dose of VARIVAX was exposed to a temperature excursion of 11.9 Fahrenheit (F) during a timeframe of 117 hours, which was detected by a digital data logger. The vaccine was reconstituted with properly stored sterile diluent. There were no previous temperature excursions. No adverse event. This is one of seven reports received from the same reporter. Sender's Comments: US-009507513-1903USA001826; US-009507513-1903USA002595; US-009507513-1903USA002596; US-009507513-1903USA002597; US-009507513-1903USA002599; US-009507513-1903USA002600.
Observed patient fall limp while sitting on bed against wall, nursing notified physician, upon physician arrival patient was AAOx3 within 1 minute, laid patient back onto bed and held legs above level of heart, patient was able to leave within 30 minutes with family at side and no other episodes.
Patient received Covid-19 Moderna vaccine on 6/23/2021. She came to the pharmacy on 6/29/2021 to report that she noticed that she developed some reaction to the vaccine. She said that she observed some kind of lumps (hard swellings on the surface of her skin) that are swollen and  warm to touch on various parts of her body- on the neck, arms, abdomen, soles  of her feet and palms of her hand